Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

Tommy Alfaro, Nihar Desai, Carol Chen, Maria Queralt Salas, Igor Novitzky-Basso, Wilson Lam, Ivan Pasic, Arjun Datt Law, Fotios Michelis, Jeffrey H. Lipton, Armin Gerbitz, Rajat Kumar, Dennis Dong Hwan Kim, Jonas Mattsson, Auro Viswabandya

Blood (2024) 144 (Supplement 1): 2183.

https://doi.org/10.1182/blood-2024-199206

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Journal Articles

The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation

Tommy Alfaro, Nihar Desai, Maria Queralt Salas, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Law, Jeffrey H. Lipton, Fotios Michelis, Igor Novitzky-Basso, Jonas Mattsson, Auro Viswabandya

Blood (2024) 144 (Supplement 1): 7289.

https://doi.org/10.1182/blood-2024-205817

Published: 2024

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Tommy Alfaro, Maria Queralt Salas, Eshetu Atenafu, Ora Bascom, Leeann Wilson, Carol Chen, Arjun D. Law, Armin Gerbitz, Auro Viswabandya, Fotios Michelis, Jeffrey H. Lipton, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Dong Hwan Kim, Jonas Mattsson, Ivan Pasic, Rajat Kumar

Blood (2023) 142 (Supplement 1): 5094.

https://doi.org/10.1182/blood-2023-191009

Published: 2023

Journal Articles

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Yomna Eissa, Eshrak Al-Shaibani, Carol Chen, Shiyi Chen, Igor Novitzky-Basso, Arjun D. Law, Wilson Lam, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Ivan Pasic, Dennis D. H. Kim, Jeffrey H. Lipton, Jonas Mattsson, Rajat Kumar

Blood (2023) 142 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2023-181118

Published: 2023

Journal Articles

Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse

Tommy Alfaro, Anne Tierens, Mariana Pinto Pereira, Arjun D. Law, Armin Gerbitz, Auro Viswabandya, Fotios V. Michelis, Jeffrey H. Lipton, Ivan Pasic, Rajat Kumar, Wilson Lam, Jonas Mattsson, Igor Novitzky-Basso, Dennis D.H. Kim

Blood (2022) 140 (Supplement 1): 10559–10560.

https://doi.org/10.1182/blood-2022-168998

Published: 2022

Journal Articles

Influence of Conditioning Regimen Intensity on Outcomes Post-Allogeneic Transplantation for AML in Complete Morphological Remission

Tommy Alfaro, Fotios V. Michelis, Jonas Mattsson, Ivan Pasic, Mats Remberger, Auro Viswabandya, Dennis D.H. Kim, Igor Novitzky-Basso, Rajat Kumar, Jeffrey H. Lipton, Wilson Lam, Arjun D. Law, Armin Gerbitz

Blood (2022) 140 (Supplement 1): 12840–12841.

https://doi.org/10.1182/blood-2022-162279

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Michael W. Deininger, Tim H Brummendorf, Jeffrey H. Lipton, Dragana Milojkovic, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3913–3915.

https://doi.org/10.1182/blood-2022-163276

Published: 2022

Journal Articles

A Primed Neutrophil Subset Predicts the Risk of Bloodstream Infections in Allogenic Bone Marrow Transplant Patients: A Prospective Study

Omnia Elebyary, Noah Fine, Chunxiang Sun, Sourav T Saha, Erin Watson, Bryan Coburn, Jeffrey H. Lipton, Michael Glogauer

Blood (2022) 140 (Supplement 1): 10475.

https://doi.org/10.1182/blood-2022-170013

Published: 2022

Journal Articles

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

María Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 4878–4879.

https://doi.org/10.1182/blood-2022-170142

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Predictors of Disease Progression and Survival in Patients with Myelodysplastic Syndrome Secondary to Inherited Bone Marrow Failure Syndromes

Blood (2022) 140 (Supplement 1): 11461–11462.

https://doi.org/10.1182/blood-2022-169965

Published: 2022

Journal Articles

Impact of Cytomegalovirus (CMV) Sero-Conversion Pre Allogeneic Stem Cell Transplant on Post-Transplant Outcomes

Ayman Sayyed, Leeann Wilson, Vered Stavi, Shiyi Chen, Jonas Mattsson, Jeffrey H. Lipton, Dennis D.H. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun D. Law, Armin Gerbitz, Ivan Pasic, Igor Novitzky-Basso, Fotios V. Michelis

Blood (2022) 140 (Supplement 1): 10491–10492.

https://doi.org/10.1182/blood-2022-158625

Published: 2022

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

Maria Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Tommy Alfaro Moya, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 7625–7627.

https://doi.org/10.1182/blood-2022-170267

Published: 2022

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Sr., Armin Gerbitz, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar

Blood (2021) 138 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2021-146275

Published: 2021

NARROW

Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse

Influence of Conditioning Regimen Intensity on Outcomes Post-Allogeneic Transplantation for AML in Complete Morphological Remission

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

A Primed Neutrophil Subset Predicts the Risk of Bloodstream Infections in Allogenic Bone Marrow Transplant Patients: A Prospective Study

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Predictors of Disease Progression and Survival in Patients with Myelodysplastic Syndrome Secondary to Inherited Bone Marrow Failure Syndromes

Impact of Cytomegalovirus (CMV) Sero-Conversion Pre Allogeneic Stem Cell Transplant on Post-Transplant Outcomes

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only